InfuSystem Hlds

InfuSystem Holdings, Inc. engages in the provision of healthcare services. It operates through the Integrated Therapy Services and Durable Medical Equipment segments. The Integrated Therapy Services segment focuses on providing electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics, and hospital outpatient oncology clinics. The Durable Medical Equipment segment is involved in the rental, sale or leasing of pole-mounted and ambulatory infusion pumps to oncology practices, hospitals, and other clinical settings. The company was founded in August 2005 and headquartered in Rochester Hills, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InfuSystem reports revenue growth but faces supply chain challenges

InfuSystem's Q4 2022 performance showed revenue growth but a decrease in adjusted EBITDA, with a focus on strategic partnerships and conservative guidance for 2023.
The company faces challenges with supply chain issues, reporting delays, and internal control deficiencies, but is actively addressing these issues.
Opportunities lie in expanding the supplier base, enhancing product offerings, and expecting gradual revenue growth in 2023, supported by key partnerships and growth initiatives.

InfuSystem reports record Q1 revenue, expands partnerships for growth

InfuSystem's Q1 2023 performance reflects strong revenue growth, successful partnerships, and strategic expansions, positioning the company for continued success in the healthcare services sector.
While facing challenges such as higher expenses and reimbursement complexities, InfuSystem's focus on innovation and financial stability underscores its resilience and growth potential.
By reaffirming annual guidance and emphasizing sustainable growth strategies, InfuSystem demonstrates a clear vision for driving profitability and market leadership in the coming quarters.

InfuSystem reports robust Q2 earnings, eyes growth in Wound Care

InfuSystem Holdings, Inc. delivered a strong performance in Q2 2023, driven by revenue growth and strategic business decisions. The company's financial results, progress in addressing internal control deficiencies, and raised guidance indicate a positive outlook for future growth. While challenges exist in scaling certain business segments, InfuSystem is well-positioned to capitalize on opportunities in Wound Care and the Sanara joint venture.

InfuSystem reports record Q3 revenue growth and strategic expansion plans

InfuSystem's Q3 2023 performance reflects robust revenue growth, improved profitability, and strategic initiatives for future expansion and operational efficiency.
While facing challenges such as margin pressures and market competition, the company's strengths in oncology and operational enhancements position it for long-term success.
Opportunities in revenue diversification, service expansion, and market presence offer InfuSystem avenues for sustained growth and profitability.
Overall, InfuSystem's strong financial results, strategic focus on growth drivers, and optimism for future performance paint a positive outlook for investors and stakeholders.

InfuSystem Hlds (INFU) reports record revenue in Q4 2023

InfuSystem Hlds (INFU) delivered a robust performance in Q4 2023, showcasing revenue growth and margin improvement. With a strategic focus on core business expansion and operational excellence, the company aims for steady growth in 2024 amidst industry challenges and regulatory changes.

InfuSystem reports strong Q1 revenue growth and strategic partnerships

InfuSystem's Q1 performance reflects revenue growth and profitability improvements driven by operational enhancements.
The company's strategic partnerships and focus on high-potential opportunities position it for sustained growth.
Challenges include market focus shifts and balancing expenses with revenue growth for long-term success.
Overall, InfuSystem's performance outlook remains positive, with confidence in achieving revenue and EBITDA targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InfuSystem Holdings, Inc. engages in the provision of healthcare services. It operates through the Patient Services and Device Solutions segments. The Patient Services segment involves the durable medical equipment, clinic-to-home health care, logistics and billing, and oncology business. The Device Solutions segment includes the sale or rent of new and pre-owned pole-mounted and ambulatory infusion pumps, treatment-related consumables, biomedical recertification, maintenance and repair services for oncology practices. The company was founded by Steven E. Watkins in August 2005 and headquartered in Rochester Hills, MI.

InfuSystem to Report Third Quarter 2022 Financial Results on November 8, 2022

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Appoints R. Rimmy Malhotra to the Board of Directors

InfuSystem Appoints R. Rimmy Malhotra to the Board of Directors

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate in Lake Street's 6th Annual Best Ideas Growth (BIG6) Conference September 14, 2022

InfuSystem to Participate in Lake Street's 6th Annual Best Ideas Growth (BIG6) Conference September 14, 2022

InfuSystem Holdings Inc. (NYSE:INFU ) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Company Participants Joe Dorame - IR, Lytham Partners Rich DiIorio - CEO Barry Steele - CFO Conference Call Participants Brooks O'Neil - Lake Street Capital Jim Sidoti - Sidoti & Company Operator Good day and welcome to the InfuSystem Holdings Incorporated Reports Second Quarter Fiscal Year 2022 Financial Results Conference Call. All participants will be in listen-only mode.

InfuSystem Holdings Inc. (INFU) CEO Rich DiIorio on Q2 2022 Results Earnings Call Transcript

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports Second Quarter 2022 Financial Results

InfuSystem Reports Second Quarter 2022 Financial Results

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Second Quarter 2022 Financial Results on August 4, 2022

InfuSystem to Report Second Quarter 2022 Financial Results on August 4, 2022

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem and Ventis Pharma Announce National Sales and Marketing Agreement for Pain Management

InfuSystem and Ventis Pharma Announce National Sales and Marketing Agreement for Pain Management

After stumbling throughout much of 2021 and early 2022 to meet analyst expectations, INFU has righted the ship and looks to have a strong back half of 2022 in store. Investors seemed to have been spooked by a delay in finalizing a contract with GE Healthcare, but the now-revealed details of the situation are extremely bullish.

InfuSystem Business Is Back On Track

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate at Craig-Hallum 19th Annual Institutional Investor Conference on Wednesday, June 1, 2022

InfuSystem to Participate at Craig-Hallum 19th Annual Institutional Investor Conference on Wednesday, June 1, 2022

InfuSystem Holdings Inc. (NYSE:INFU ) Q1 2022 Results Conference Call May 5, 2022 9:00 AM ET Company Participants Joe Dorame - IR, Lytham Partners Rich DiIorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and Chief Operating Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Brooks O'Neil - Lake Street Capital Jim Sidoti - Sidoti & Company Aaron Warwick - Breakout Investors Operator Ladies and gentlemen, good day, and thank you all for joining this InfuSystem Holdings Q1 Fiscal Year 2022 Financial Results Conference Call. As a reminder, all participants are in a listen-only but later you will have the opportunity to ask questions during our question-and-answer session.

InfuSystem Holdings Inc. (INFU) CEO Rich DiIorio on Q1 2022 Results - Earnings Call Transcript

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports First Quarter 2022 Financial Results

InfuSystem Reports First Quarter 2022 Financial Results

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces Master Service Agreement with Leading Global Healthcare Technology and Diagnostic Company

InfuSystem Announces Master Service Agreement with Leading Global Healthcare Technology and Diagnostic Company

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report First Quarter 2022 Financial Results on May 5, 2022

InfuSystem to Report First Quarter 2022 Financial Results on May 5, 2022

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces Agreement with Solo-Dex for Continuous Peripheral Nerve Block Catheters

InfuSystem Announces Agreement with Solo-Dex for Continuous Peripheral Nerve Block Catheters

InfuSystem Holdings Inc (NYSE: INFU) has announced a national distribution agreement with Solo-Dex Inc for its proprietary continuous nerve block catheters. With Solo-Dex catheter over the needle technology, all anesthesiologists can place facile continuous peripheral.

InfuSystem Inks Distribution Pact For Solo-Dex's Continuous Peripheral Nerve Block Catheters

INFU surprised investors by pre-releasing disappointing FY21 results, leading to a 25% selloff in shares the same day. Nothing about INFU's long-term trajectory changed as the 4Q21 miss is understandable and temporary, relating to Omicron disruptions and a delay in contract execution with one partner.

InfuSystem: A Possible Goldmine After Recent Stumble

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021

InfuSystem Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Preliminary Fourth Quarter and Full Year 2021 Financial Results on February 10, 2022

InfuSystem to Report Preliminary Fourth Quarter and Full Year 2021 Financial Results on February 10, 2022

Inuvo

Quipt Home Medical Corp

Smith Micro Software

TechPrecision Corp

The market dropped precipitously in January 2022, with the Russell 2000 down by nearly 10%. Like many sudden market “corrections,” this one “threw out the baby with the bath water,” meaning virtually all stocks were hammered regardless of their underlying fundamentals.

January Correction Leads To Attractive Opportunities

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Present at Sidoti Winter Virtual Investor Conference on Wednesday, January 19, 2022

InfuSystem to Present at Sidoti Winter Virtual Investor Conference on Wednesday, January 19, 2022

Following a sharp drop in stock price after announcing a mid-year pivot in short-term strategy, INFU shares have recovered some of those lost gains, but much upside is still left. Management has shown credibility by landing several new deals that will lead to significant revenue and AEBITDA growth for at least the next five years.

Weather Cooling Down, But InfuSystem Heating Up

InfuSystem Holdings Inc. (INFU) CEO Richard DiIorio on Q3 2021 Results - Earnings Call Transcript

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem reports third quarter financial results, reaffirms 2021 guidance

InfuSystem Reports Third Quarter 2021 Financial Results

InfuSystems Holdings, Inc. (INFU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate InfuSystems Holdings, Inc. (INFU) to Report a Decline in Earnings: What to Look Out for

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to report third quarter 2021 financial results on November 15, 2021

News for InfuSystem Hlds Stock (INFU)